1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. DIAC Co., Ltd.
  6. News
  7. Summary
    A078590   KR7078590007

DIAC CO., LTD.

(A078590)
  Report
End-of-day quote Korea Stock Exchange  -  03-22
3890.00 KRW   -10.57%
05/11Diac to Raise $7.8 Million via Share Issuance
MT
04/22DIAC 2022 ARBITRATION RULES : Will They Propel DIAC Into A Top-Five Institution?
AQ
04/11Dubai International Arbitration Centre (DIAC) Issues Long-awaited Revised Arbitration Rules
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Quest PharmaTech Inc. Announces Two Presentations by Oncoquest Pharmaceuticals, Inc. At the 2021 Annual Meeting of the American Association of Clinical Oncologists

06/01/2021 | 03:18pm EDT

Quest PharmaTech Inc. announced that clinical investigators working with OncoQuest Pharmaceuticals Inc. (OQP) lead clinical candidate oregovomab, will be making two presentations as part of the American Society of Clinical Oncology (ASCO) conference proceedings. OQP acquired oregovomab from OncoQuest Inc., one of the equity investee companies (45%) of Quest PharmaTech Inc. The first presentation by Dr. Angeles Alvarez Secord, Principal Investigator and Associate Director of Clinical Research at Duke Cancer Institute of Duke University will update the research community on progress with the ongoing FLORA 5 phase III clinical study of front-line carboplatin-paclitaxel-oregovomab chemotherapy. This double blind and placebo controlled multinational trial is currently accruing patients at centers in the US, Canada, Europe and Asia and is adding additional centers and participating geographies. This study seeks to confirm the observations of Brewer et al in Gynecologic Oncology 2020 that demonstrated how oregovomab in combination with carboplatin and paclitaxel could dramatically improve both progression free and overall survival relative to chemotherapy in the absence of incremental toxicity. The second oregovomab report at ASCO being presented by Dr. Robert Holloway, Medical Director of the Gynecologic Oncology Program at Florida Hospital is an abstract presentation of the results from the Phase 1b oregovomab clinical trial protocol ORE-QPT-003H. The report titled, "Final survival follow up and translational associations using interval indirect immunization with oregovomab (O) and poly ICLC (Hiltonol®) (H) in patients (pts) with recurrent platinum resistant ovarian cancer" evaluated heavily pretreated patients with recurrent ovarian cancer receiving an indirect immunization with oregovomab in combination with the TLR3 agonist polyICLC (Hiltonol®). The median OS was 15 months in this advance disease population and 4 patients remained alive at the data lock. The study established that Hiltonol® is a suitable candidate for augmenting immune response in the immune suppressed heavily advanced disease population and pointed to novel approaches to the management of this difficult and unmet medical need.


© S&P Capital IQ 2021
All news about DIAC CO., LTD.
05/11Diac to Raise $7.8 Million via Share Issuance
MT
04/22DIAC 2022 ARBITRATION RULES : Will They Propel DIAC Into A Top-Five Institution?
AQ
04/11Dubai International Arbitration Centre (DIAC) Issues Long-awaited Revised Arbitration R..
AQ
03/16THE DIAC ARBITRATION RULES 2022 : A Step To Cement The DIAC's Position As A Prominent Arbi..
AQ
02/22DBRS Morningstar Assigns Rating to Cars Alliance Auto Leases France Master Class A 2022..
AQ
2021OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investig..
CI
2021OncoQuest Pharmaceuticals Inc. completed the spin-off of OQP BIO Inc.
CI
2021OncoQuest Pharmaceuticals Inc. completed the spin-off of Dual Moolsan Holdings Co., Ltd..
CI
2021Quest PharmaTech Inc. Announces Two Presentations by Oncoquest Pharmaceuticals, Inc. At..
CI
2021The Board of Directors of OncoQuest Pharmaceuticals Inc. announced to spin-off biotechn..
CI
More news
Financials
Sales 2020 61 405 M 47,9 M 47,9 M
Net income 2020 -179 510 M -140 M -140 M
Net Debt 2020 4 001 M 3,12 M 3,12 M
P/E ratio 2020 -2,09x
Yield 2020 -
Capitalization 323 B 252 M 252 M
EV / Sales 2019 1,24x
EV / Sales 2020 6,64x
Nbr of Employees 94
Free-Float 92,8%
Chart DIAC CO., LTD.
Duration : Period :
DIAC Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Chang-Hyun Lee Chief Executive Officer
Ragupathy G. Madiyalakan Chairman
Sunil Gupta Chief Medical Officer
Jong-Seok Woo Independent Director
Cheol-Geun Yoo Independent Director
Sector and Competitors